RedHill Biopharma (RDHL) AI Stock Analysis

• Market Cap: $3.12M
• Dividend Yield: N/A
• Average Volume (3M): 1.01M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.85
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 35
• Sector: Healthcare
• Sector Strength: 47
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): N/A
• Shares Outstanding: 2,295,345
• 10 Day Avg. Volume: 136,545
• 30 Day Avg. Volume: 1,007,934
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $2.00
• Price Target Upside: 50.38% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 41 Neutral
• Price Target: $2.00 ▲(50.38% Upside)

The most significant risk comes from financial performance, with negative margins and cash flow problems posing major challenges. Technical analysis supports a bearish trend. Lack of valuation data and earnings call information limits further insights.

RedHill Biopharma Business Overview & Revenue Model

Company Description

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

How the Company Makes Money

RedHill Biopharma makes money through the development, marketing, and sale of its proprietary drug formulations targeting gastrointestinal and infectious diseases. The company's revenue primarily comes from the commercialization of its core products, which include approved and marketed drugs as well as those in different stages of clinical development. Significant partnerships with other pharmaceutical companies may also contribute to its earnings, allowing for strategic collaborations in drug development and distribution. Revenue streams are further bolstered by licensing agreements and potential milestone payments associated with the advancement of its drug pipeline.

RedHill Biopharma Financial Statement Overview

Summary

RedHill Biopharma is facing significant financial challenges, with negative net profit margins and cash flow issues. The balance sheet reflects high leverage and financial distress, which are critical concerns.

Income Statement

The company's revenue has shown inconsistent growth with recent declines from previous highs. The gross profit margin has been relatively healthy, but the net profit margin is negative due to high EBIT losses, indicating challenges in managing costs effectively. There is a significant negative EBIT and EBITDA margin, reflecting operational inefficiencies.

Balance Sheet

The balance sheet reveals a concerning financial structure with negative stockholders' equity in recent years, indicating potential financial distress. The debt-to-equity ratio is not meaningful due to negative equity, and the equity ratio is negative, suggesting high leverage and risk.

Cash Flow

Cash flow statements show negative operating and free cash flows, indicating cash burn and financial strain. Despite positive financing cash flows, the operating cash flow to net income and free cash flow to net income ratios are negative, pointing to insufficient cash generation from operations.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	8.04M	6.51M	61.80M	85.76M	64.36M
Gross Profit	4.85M	3.05M	28.46M	36.35M	27.47M
EBITDA	-7.59M	26.27M	-42.84M	-63.03M	-54.94M
Net Income	-8.27M	23.92M	-71.67M	-97.74M	-76.17M
Balance Sheet
Total Assets	18.04M	23.05M	158.87M	181.19M	180.24M
Cash, Cash Equivalents and Short-Term Investments	4.62M	6.36M	19.98M	38.00M	29.79M
Total Debt	356.00K	1.17M	122.69M	87.81M	86.90M
Total Liabilities	22.73M	20.98M	207.27M	172.31M	166.38M
Stockholders Equity	-4.68M	2.07M	-48.40M	8.88M	13.86M
Cash Flow
Free Cash Flow	-9.38M	-35.83M	-29.38M	-65.16M	-102.35M
Operating Cash Flow	-9.37M	-35.82M	-29.18M	-65.05M	-48.58M
Investing Cash Flow	-9.00K	―	8.30M	-8.14M	-35.65M
Financing Cash Flow	8.42M	21.38M	11.45M	73.46M	84.37M

RedHill Biopharma Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.33
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RDHL, the sentiment is Negative. The current price of 1.33 is above the 20-day moving average (MA) of 1.31, below the 50-day MA of 1.69, and below the 200-day MA of 3.71, indicating a neutral trend. The MACD of -0.09 indicates Negative momentum. The RSI at 42.49 is Neutral, neither overbought nor oversold. The STOCH value of 38.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RDHL.

RedHill Biopharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.83B	-0.18	-40.10%	2.29%	21.46%	-2.03%
SNOA	51 Neutral	$7.92M	―	-78.73%	―	17.43%	75.52%
UPC	45 Neutral	$2.12M	―	2.66%	―	-27.81%	―
RDHL	41 Neutral	$3.12M	―	1155.92%	―	―	―
CPHI	41 Neutral	$4.50M	―	-52.05%	―	-29.64%	73.63%
PRFX	34 Underperform	$3.28M	―	-129.08%	―	―	―
SHPH	32 Underperform	$3.65M	―	-551.04%	―	―	31.53%